Verona Pharma Is Maintained at Buy by Canaccord Genuity
Express News | Verona Pharma PLC : Canaccord Genuity Raises Target Price to $37 From $35
Analysts Have Conflicting Sentiments on These Healthcare Companies: Astellas Pharma (OtherALPMF) and Verona Pharma (VRNA)
CCORF Maintains Verona Pharma(VRNA.US) With Buy Rating, Raises Target Price to $37
European Equities Traded in the US as American Depositary Receipts Trend Lower Friday; Set to End Week Down 4%
European Equities Traded in the US as American Depositary Receipts Trend Lower Thursday
European Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading
European Equities Traded in the US as American Depositary Receipts Start Week Lower in Monday Trading
European Equities Traded in the US as American Depositary Receipts Rise Slightly in Thursday Trading
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading
H.C. Wainwright Maintains Verona Pharma(VRNA.US) With Buy Rating, Maintains Target Price $36
Buy Rating on Verona Pharma: FDA Approval and Strong Market Entry Prospects for Ohtuvayre
Express News | Truist Securities Maintains Buy on Verona Pharma, Raises Price Target to $38
CCORF Maintains Verona Pharma(VRNA.US) With Buy Rating, Maintains Target Price $35
Truist Financial Maintains Verona Pharma(VRNA.US) With Buy Rating
Express News | Verona Pharma PLC : Truist Securities Raises Target Price to $38 From $32
First Inhaled COPD Therapy In Over 2 Decades - FDA Approves Verona Pharma's First Commercial Product
Express News | Canaccord Genuity Maintains Buy on Verona Pharma, Maintains $35 Price Target
Ligand Pharmaceuticals' Partner Gets US FDA Approval for Ohtuvayre to Treat Chronic Obstructive Pulmonary Disease